Metabasis Updates Findings on Diabetes Drug

Xconomy San Diego — 

San Diego’s Metabasis Therapeutics said in Barcelona, Spain, yesterday that a diabetes drug it has under development was found to be safe and well-tolerated in a phase 2a clinical trial. The findings reported by the company at the World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension follow its initial proof-of-concept trial for MB07803, which inhibits the enzyme FBPase in the liver.